Physician profile

John Vanwoert

Obstetrics & Gynecology · Monroe, WI

NPI 1861428294

$260.08

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$50.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $59.46 2019-2020
Ethicon US, LLC $36.56 2023 Echelon Flex, Echelon Circular, Endopath Xcel
Duchesnay USA Incorporated $31.05 2019
Coopersurgical, INC. $22.43 2022
Hologic Sales and Service, LLC $19.80 2019
Bayer Healthcare Pharmaceuticals INC. $17.66 2019
Therapeuticsmd, INC. $17.45 2019
Lupin INC. $16.72 2020
Exeltis, USA INC. $13.65 2023 Slynd
Amag Pharmaceuticals, INC. $12.84 2019
Pfizer INC. $12.46 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Vanwoert

$260.08

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/220870/john-vanwoert

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.